Figure S4 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Key Points

• Co-targeting bcl-xl and mcl-1 led to significant protein changes in models, indicating potential treatment synergy.
• Combination treatment showed distinct effects on protein levels compared to single treatments, highlighting efficacy.
• The approach included time-course assessment after 24 hours using various inhibitors for comparative analysis.
• Findings suggest that dual targeting may enhance therapeutic outcomes in cancer with AR-V7 expression, emphasizing need for further studies.